**Core tip:** The incidence of inflammatory bowel disease, a chronic intestinal inflammatory disorder that includes Crohn's disease (CD) and ulcerative colitis is rising. Our previous study revealed that hsa_circRNA_102610 is upregulated in CD patients. However, further investigation is required to explore how hsa_circRNA_102610 participates in the pathogenesis of CD. The results of this study indicate that hsa_circRNA_102610 overexpression in CD patients could accelerate the proliferation and epithelial-mesenchymal transition of intestinal epithelial cells *via* sponging of hsa-miR-130a-3p. Thus, hsa_circRNA_102610 may promote CD progression. Hsa_circRNA_102610 may serve as a potential target for CD therapy and novel drug research. Exogenously delivered hsa-miR-130a-3p could possibly act as a sponge of hsa_circRNA_102610.

INTRODUCTION
============

Circular RNAs (circRNAs) are endogenous covalently closed circular biomolecules generated by back-splicing. Due to their unique structure without a 5'cap or 3'poly A tail, circRNAs are more stable than linear RNAs, such as microRNAs (miRNAs) and lncRNAs. They are expressed in eukaryotes with tissue-specific and disease-specific characteristics\[[@B1]\]. Thus, circRNAs are potential biomarkers for disease prediction, diagnosis and prognostic analysis.

To date, circRNAs have been confirmed to participate in various diseases, including colorectal cancer, hepatic carcinoma and rheumatoid arthritis\[[@B2]-[@B5]\]. CircRNAs are also considered valuable diagnostic biomarkers for Crohn's disease (CD)\[[@B6]-[@B8]\]. Among the known biological functions of circRNAs, the miRNA-sponging function is one of the most extensively studied. By this mechanism, circRNAs can act as competing endogenous RNAs due to the presence of similar miRNA-binding site sequences on the mRNA targets of the corresponding miRNAs\[[@B9],[@B10]\]. Our previous study demonstrated that hsa_circRNA_102610 was upregulated in CD patients\[[@B7]\]. Furthermore, miRNA response element (MRE) analysis suggested the existence of a potential interaction between hsa_circRNA_102610 and hsa-miR-130a-3p.

Hsa-miR-130a-3p is generally considered a tumor suppressor because it is downregulated in multiple types of cancers\[[@B11]\]. In addition, it participates in various biological processes related to tumorigenesis, such as epithelial mesenchymal transition (EMT), cell viability-related processes, invasion and apoptosis\[[@B12]-[@B16]\]. Overexpression of hsa-miR-130a-3p markedly inhibits GC cell EMT and tumorigenesis, by targeting TBL1XR1 to induce E-cadherin expression and reduce N-cadherin, Twist, and MMP2 expression\[[@B11]\]. Moreover, a mothers against dec-apentaplegic homolog 4 (SMAD4)-dependent mechanism was recently discovered to inhibit transforming growth factor-β1 (TGF-β1)-induced EMT *via* hsa-miR-130a-3p in EC-1 cells, resulting in upregulation of E-cadherin and downregulation of N-cadherin and Vimentin\[[@B13]\].

Current evidence supports the view that EMT plays an important role in CD pathogenesis. Intestinal fibrosis accompanying CD is triggered by multiple factors. EMT induced by TGF-β or IL-13 makes an important contribution to fibrosis by inducing the generation of new mesenchymal cells from the epithelium\[[@B17],[@B18]\]. Moreover, miRNAs have been confirmed to participate in the regulation of the pathologic processes of inflammatory bowel disease (IBD). Downregulation of the miR-200 family (miR-141, miR-200a, miR-200c and miR-429) in the epithelium of fibrotic CD intestinal tissue accompanied by significantly elevated rates of cytokeratin-18 or Vimentin-positive epithelial staining in CD strictures is associated with EMT\[[@B19]\]. Functional studies have demonstrated that miR-200b can inhibit TGF-β1-induced EMT in IECs\[[@B20]\].

With regard to hsa-miR-130a-3p, there are no research reports on its role in CD. Thus, according to the MRE analysis results, we hypothesized that the expression of hsa-miR-130a-3p might be reduced in CD patients and that hsa_circRNA_102610 might participate in the regulation of hsa-miR-130a-3p and its downstream pathway proteins. In this study, a correlation analysis between hsa_circRNA_102610 and hsa-miR-130a-3p expression was carried out in CD patients. Further studies were performed to explore the mechanism by which hsa_circRNA_102610 regulates hsa-miR-130a-3p and its downstream proteins related to EMT and cell proliferation.

MATERIALS AND METHODS
=====================

Sample collection and reverse transcription quantitative polymerase chain reaction analysis
-------------------------------------------------------------------------------------------

Recently diagnosed CD patients and healthy controls were recruited at Suzhou Affiliated Hospital of Nanjing Medical University (Suzhou, Jiangsu Province, China) from 2018 to 2019. The sample collection methods were described in our previous study\[[@B7]\]. Informed consent was obtained from all the participants. Ethical approval was obtained from the Ethics Committee of Nanjing Medical University. The methods of RNA extraction and reverse transcription quantitative polymerase chain reaction (RT-qPCR) were described in our previous study\[[@B7]\]. Primers for RT-qPCR are listed in Table [1](#T1){ref-type="table"}.

###### 

Primers for reverse transcription quantitative polymerase chain reaction

  **Primer**           **Forward (5'-3')**       **Reverse (5'-3')**
  -------------------- ------------------------- --------------------------
  miR130a-3p           GATGCTCTCAGTGCAATGTTA     TATGGTTGTTCTGCTCTCTGTCTC
  U6                   ATTGGAACGATACAGAGAAGATT   GGAACGCTTCACGAATTTG
  hsa_circRNA_102610   ACAGTGTGCCAAGTTACTCG      AGTGCAAGATAAAGGCCCAA
  β-actin              GTGGCCGAGGACTTTGATTG      CCTGTAACAACGCATCTCATATT

RT-qPCR: Reverse transcription quantitative polymerase chain reaction; β-actin: Beta-actin.

Overexpression or silencing of hsa_circRNA_102610
-------------------------------------------------

A hsa_circRNA_102610 overexpression plasmid was constructed in pLC5-ciR by Geneseed (Guangzhou, Guangdong, China). Small interfering RNA (siRNA) targeting the splice junction region of hsa_circRNA_102610 was synthesized by GenePharma (Shanghai, China).

Hsa-miR-130a-3p mimics and inhibitor
------------------------------------

Hsa-miR-130a-3p mimics and hsa-miR-130a-3p inhibitor were synthesized by GenePharma. The sequences are listed in Table [2](#T2){ref-type="table"}.

###### 

Sequences of RNA oligo and probes

  **RNA**                     **Sequence (5\'-3\')**
  --------------------------- ----------------------------------------------
  hsa_circRNA_102610 si-1     GCUGAUUUUUCAGGGUCAATTUUGACCCUGAAAAAUCAGCTT
  hsa_circRNA_102610 si-2     UUCAGGGUCAACUUUGUAGTTCUACAAAGUUGACCCUGAATT
  hsa-miR-130a-3p mimics      CAGUGCAAUGUUAAAAGGGCAUGCCCUUUUAACAUUGCACUGUU
  hsa-miR-130a-3p inhibitor   AUGCCCUUUUAACAUUGCACUG
  hsa_circRNA_102610 probe    FAM-GCACACTACAAAGTTGTTGACCCTGAAAAATCAGCAGAA
  hsa-miR-130a-3p probe       CY3-ATGCCCTTTTAACATTGCACTG

Hsa_circRNA_102610 si-1: The first sequence of small interfering RNA against hsa_circRNA_102610; Hsa_circRNA_102610 si-2: The second sequence of small interfering RNA against hsa_circRNA_102610.

Cell culture and transfection
-----------------------------

Human intestinal epithelial cells (HIECs) and normal-derived colon mucosa cell line 460 (NCM460) cells were cultured in Roswell Park Memorial Institute 1640 Medium or Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Cells at 60%-70% confluence were transfected with the hsa_circRNA_102610 overexpression plasmid hsa\_ circRNA_102610-pLC5-ciR, the hsa-miR-130a-3p mimics, the hsa-miR-130a-3p inhibitor, or hsa_circRNA_102610 siRNA fragments with Lipofectamine 3000 (Life Technologies, Carlsbad, CA, United States) according to the manufacturer's instructions for 48 h.

Cell cycle detection by flow cytometry
--------------------------------------

HIECs and NCM460 cells were seeded in 60 mm cell culture dishes. Cells at 60-70% confluence were transfected according to the above protocol. Subsequently, the cells were fixed with precooled 70% ethanol overnight at -20°C and labeled with propidium iodide (PI, Beyotime, Shanghai, China). The cell cycle distribution was detected by flow cytometry (FACSCalibur, BD, San Jose, CA, United States).

Cell counting kit-8 assay and 5-ethynyl-2'-deoxyuridine staining
----------------------------------------------------------------

HIECs and NCM460 cells were seeded in 24-well plates at a density of 2 × 10^4^ cells/mL. Cells at 60-70% confluence were transfected according to the above protocol the next day. On the third day, cells were harvested and reseeded in 96-well plates at a density of 2 × 10^4^ cells/mL. A cell counting kit-8 (CCK-8) (Dojindo, Shanghai, China) was used to detect cell viability. A Cell-Light™ 5-ethynyl-2'-deoxyuridine (EdU) Apollo^®^567 In Vitro Imaging Kit (RiboBio, Guangzhou, Guangdong, China) was used to measure the cellular proliferation rate.

Bioinformatics analysis
-----------------------

MiRNAs that may bind to hsa_circRNA_102610 were predicted by TargetScan and miRanda. The top 5 miRNAs potentially binding to microRNA response elements in hsa_circRNA_102610 were predicted by Arraystar's custom miRNA target prediction software (Arraystar, Rockville, MD, United States).

Target mRNAs of miRNAs were predicted by TargetScan7.1 and miRDB_V5.0. Pathway analysis of the upregulated circRNAs in CD was performed with the Database for Annotation, Visualization and Integrated Discovery. A network containing hsa_circRNA_102610, the top 5 potentially binding miRNAs, and their target genes was generated by Cytoscape 3.7.0.

CircRNAs determined to be upregulated in CD patients in our previous study related to EMT were chosen according to their predicted binding miRNAs. A hierarchical clustering analysis of target circRNAs was performed by MeV based on expression values.

Fluorescence in situ hybridization
----------------------------------

The expression level and location of hsa_circRNA_102610 or hsa-miR-130a-3p were detected by fluorescence in situ hybridization (FISH) using FAM- and CY3-labeled specific probes, respectively (GenePharma, Shanghai, China). 4', 6-diamidino-2-phenylindole was used to stain cell nuclei. Cellular fluorescence images were collected by a confocal laser scanning microscope (Carl Zeiss, Göschwitzer Strasse, Jena, Germany). The sequences of the probes are listed in Table [2](#T2){ref-type="table"}.

Luciferase reporter assay
-------------------------

A fragment containing a total of 273 bp of hsa_circRNA_102610 including the hsa-miR-130a-3p response element was synthesized (GenScript, Nanjing, Jiangsu Province, China) and cloned into the plasmid psiCHECK-2 (Promega, Madison, WI, United States). In addition, a counterpart containing mutations in the hsa-miR-130a-3p response element was constructed. Then, 293T and NCM460 cells were transfected with 500 ng of plasmids with Lipofectamine 3000. The relative luciferase activity was assayed by a Dual-Luciferase^®@^ Reporter Assay System (Promega, Madison, WI, United States) 48 h after transfection.

TGF-β1 induced EMT in intestinal epithelial cells
-------------------------------------------------

HIECs and NCM460 cells were treated with TGF-β1 at a concentration of 10 ng/mL for 48 h. Phase microscopy was used to observe morphological changes. The expression levels of EMT markers such as Vimentin, N-cadherin, and E-cadherin were detected by western blotting.

Western blotting
----------------

Western blotting was performed as follows: Briefly, cellular proteins of NCM460 cells and HIECs were extracted with RIPA Lysis Buffer (Beyotime, Shanghai, China) containing 1% phenylmethanesulfonyl fluoride. Proteins (30 μg/well) were separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and transferred to polyvinylidene difluoride membranes by a wet blotting system (Mini-PROTEAN^®^ Tetra, Bio-Rad, Hercules, CA, United States). The membranes were then blocked in 5% nonfat milk at room temperature for 1.5 h and incubated with primary antibodies overnight at 4°C. Primary antibodies against CyclinD1 (CST-2878S, Cell Signaling Technology, Danvers, MA, United States), SMAD4 (CST-38454S, Cell Signaling Technology, Danvers, MA, United States), N-cadherin (CST-13116S, Cell Signaling Technology, Danvers, MA, United States), E-cadherin (CST-3195S, Cell Signaling Technology, Danvers, MA, United States) and Vimentin (CST-5741S, Cell Signaling Technology, Danvers, MA, United States) were used in this study. After washing with TBST three times, the membranes were incubated with HRP-linked secondary antibodies at room temperature for 1.5 h. Tanon High-sig ECL Western Blotting Substrate (Tanon, Shanghai, China) was used to detect the signals with GAPDH as a loading control.

Statistical analysis
--------------------

Statistical significance was analyzed by GraphPad Prism 5 (GraphPad, La Jolla, CA, United States). Comparisons between two groups were performed by Student's *t*-test. One-way ANOVA test was used to determine differences among groups. Correlations between parameters were assessed by Pearson correlation coefficients. Statistical significance was considered at *P* \< 0.05.

RESULTS
=======

Upregulation of hsa_circRNA_102610 was positively correlated with fecal calprotectin level in CD
------------------------------------------------------------------------------------------------

Our previous study showed that hsa_circRNA_102610 is upregulated in CD patients. To investigate whether the upregulation of hsa_circRNA_102610 correlates with the degree of inflammation, the calprotectin (CALP) level, C-reactive protein level and erythrocyte sedimentation rate (ESR) were included in the correlation analysis. The results are shown in Figure [1](#F1){ref-type="fig"}. There was no correlation between the upregulation of hsa_circRNA_102610 (Figure [1A](#F1){ref-type="fig"}) and C-reactive protein (Figure [1B](#F1){ref-type="fig"}) or ESR level (Figure [1C](#F1){ref-type="fig"}). However, it was found that hsa_circRNA_102610 expression was positively correlated with the CALP level (Figure [1D](#F1){ref-type="fig"}).

![Correlation analysis between hsa_circRNA_102610 and erythrocyte sedimentation rate, C-reactive protein, and calprotectin in Crohn's disease patients. A: Relative expression of hsa_circRNA_102610 in Crohn's disease (CD) patients (*n* = 40) and healthy controls (HC, *n* = 40); B: Correlation analysis of hsa_circRNA_102610 and C-reactive protein in CD patients; C: Correlation analysis of hsa_circRNA_102610 and erythrocyte sedimentation rate in CD patients; D: Correlation analysis of hsa_circRNA_102610 and calprotectin in CD patients. ^b^*P* \< 0.01 *vs* HC. CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; CALP: Calprotectin; CD: Crohn's disease.](WJG-26-3034-g001){#F1}

Hsa_circRNA_102610 promotes intestinal epithelial cell proliferation
--------------------------------------------------------------------

EdU staining suggested that proliferation rates were lower among HIECs and NCM460 cells with hsa_circRNA_102610 downregulation, and higher among cells with hsa_circRNA_102610 overexpression (Figure [2A](#F2){ref-type="fig"}). In line with the EdU staining results, the CCK-8 assay showed that downregulation of hsa_circRNA_102610 decreased the viability of HIECs and NCM460 cells, while overexpression of hsa_circRNA_102610 promoted viability (Figure [2B](#F2){ref-type="fig"}). Moreover, cell cycle detection by flow cytometry demonstrated that hsa_circRNA_102610 downregulation caused cell cycle arrest in HIECs and NCM460 cells, while hsa_circRNA_102610 overexpression promoted cell cycle progression. The relative HIEC and NCM460 cell numbers in G1 phase were decreased following hsa_circRNA_102610 overexpression, while the relative numbers of cells in S phase and G2 phase were increased. The opposite results were observed with hsa_circRNA_102610 downregulation (Figure [2C](#F2){ref-type="fig"}).

![Hsa_circRNA_102610 overexpression promoted human intestinal epithelial cells and normal-derived colon mucosa cell line 460 cell proliferation. A: 5-ethynyl-2'-deoxyuridine-staining of human intestinal epithelial cells. Red: 5-ethynyl-2'-deoxyuridine staining; blue: Hoechst 33342 staining; B: Relative HIEC and normal-derived colon mucosa cell line 460 cell viability, as measured by the cell counting kit-8 assay; C: Cell cycle phase detection for HIECs and normal-derived colon mucosa cell line 460 cells by flow cytometry. ^a^*P* \< 0.05 *vs* Ctrl, ^b^*P* \< 0.01 *vs* Ctrl, ^c^*P* \< 0.001 *vs* Ctrl, ^d^*P* \< 0.0001 *vs* Ctrl. Si-1 and Si-2: siRNAs mediating hsa_circRNA_102610 downregulation. OE: Hsa_circRNA_102610 overexpression by transient transfection. Ctrl: Control; HIECs: Human intestinal epithelial cells; NCM460: Normal-derived colon mucosa cell line 460; EdU: 5-ethynyl-2'-deoxyuridine.](WJG-26-3034-g002){#F2}

Hsa_circRNA_102610 was predicted to participate in cell proliferation and EMT by sponging hsa-miR-130a-3p
---------------------------------------------------------------------------------------------------------

Gene Ontology and pathway analyses were performed to study the upregulated circRNAs (092520, 102610, 004662, and 103124) in CD, which we validated in a recently published article\[[@B7]\]. The results suggested that the AMPK and mTOR signaling pathways participate in CD pathology (Figure [3A](#F3){ref-type="fig"}). Further hierarchical clustering analysis indicated that hsa_circRNA_102610 (Figure [3B](#F3){ref-type="fig"}) was among the circRNAs associated with EMT according to MRE analysis. MRE analysis of hsa_circRNA_102610 showed the top 5 possible binding miRNAs, and hsa-miR-130a-3p was the most likely miRNA. The predicted binding sites of hsa_circRNA_102610 and these 5 miRNAs are listed in Figure [3C](#F3){ref-type="fig"}. Furthermore, a network consisting of hsa_circRNA_102610, the miRNAs and the corresponding proteins was generated by Cytoscape (Figure [3D](#F3){ref-type="fig"}). SMAD4 was one of the proteins predicted to bind to hsa-miR-130a-3p. It is generally thought that the AMPK and mTOR signaling pathways are related to cell proliferation, and hsa-miR-130a-3p could regulate EMT by controlling SMAD4 expression\[[@B13]\]. Moreover, an inverse correlation between downregulation of hsa-miR-130a-3p and upregulation of hsa_circRNA_102610 in CD patients was observed (Figure [3E](#F3){ref-type="fig"}). Thus, we infer that hsa_circRNA_102610 may participate in cell proliferation and SMAD4-related EMT by sponging hsa-miR-130a-3p.

![Functional prediction of hsa_circRNA_102610 by bioinformatics analysis. A: Pathway analysis of the validated upregulated circRNAs (092520, 102610, 004662, and 103124) in Crohn's disease (CD); B: Hierarchical clustering analysis of upregulated circRNAs in CD that might play roles in epithelial-mesenchymal transition according to miRNA response element analysis. Hsa_circRNA_102610 was included; C: miRNA response element analysis of hsa_circRNA_102610. Binding sites were predicted between hsa_circRNA_102610 and hsa-miR-130a-3p, hsa-miR-130b-3p, hsa-miR-136-5p, hsa-miR-330-3p, and hsa-miR-513a-3p. The databases miRanda and TargetScan were used for this prediction; D: Interaction network of hsa_circRNA_102610, the top 5 possibly binding miRNAs, and the corresponding proteins; E: Analysis of hsa-miR-130a-3p expression by reverse transcription quantitative polymerase chain reaction and its correlation with hsa_circRNA_102610 expression in CD patients. ^a^*P* \< 0.05 *vs* healthy controls. CD: Crohn's disease patients; HC: Healthy controls.](WJG-26-3034-g003){#F3}

Hsa-miR-130a-3p reversed the cell proliferation-promoting effect of hsa\_ circRNA_102610
----------------------------------------------------------------------------------------

To explore whether hsa-miR-130a-3p can reverse the effects of hsa_circRNA_102610 in intestinal epithelial cells, CCK-8 assays, EdU staining and cell cycle detection were performed. The results showed that the hsa-miR-130a-3p inhibitor could reverse the decrease in cell proliferation caused by hsa_circRNA_102610 downregulation (Figure [4](#F4){ref-type="fig"}). Conversely, the hsa-miR-130a-3p mimics partially attenuated the increase in NCM460 and HIEC proliferation induced by hsa_circRNA_102610 overexpression (Figure [5](#F5){ref-type="fig"}).

![Hsa-miR-130a-3p inhibitor reversed the effect of hsa_circRNA_102610 knockdown on intestinal epithelial cells. A: 5-ethynyl-2'-deoxyuridine-staining of human intestinal epithelial cells and normal-derived colon mucosa cell line 460 (NCM460) cells. Red: 5-ethynyl-2'-deoxyuridine staining; blue: Hoechst 33342 staining; B: Relative HIEC and NCM460 cell viability, as measured by the cell counting kit-8 assay; C: Cell cycle detection of human intestinal epithelial cells or NCM460 cells by flow cytometry. Control: Negative control transfected with siRNA negative control. ^a^*P* \< 0.05 *vs* Ctrl, ^b^*P* \< 0.01 *vs* Ctrl, ^c^*P* \< 0.001 *vs* Ctrl, ^d^*P* \< 0.0001 *vs* Ctrl. Si-1, Si-2, siRNA interference of hsa_circRNA_102610. Si-1+IN, Si-2+IN, cotransfection of hsa_circRNA_102610 siRNA and hsa-miR-130a-3p inhibitor. Ctrl: Control; EdU: 5-ethynyl-2'-deoxyuridine; NCM460: Normal-derived colon mucosa cell line 460; HIECs: Human intestinal epithelial cells. Bar: × 100 μm.](WJG-26-3034-g004){#F4}

![Hsa-miR-130a-3p mimics reversed the cell proliferation promoting effect of hsa_circRNA_102610 overexpression. A: 5-ethynyl-2'-deoxyuridine staining of human intestinal epithelial cells (HIECs) and normal-derived colon mucosa cell line 460 (NCM460) cells. Red: 5-ethynyl-2'-deoxyuridine stained; Blue: Hoechst 33342 stained; B: Relative HIEC and NCM460 cell viability measured by the cell counting kit-8 test; C: Cell cycle phase of HIECs for NCM460 cells by flow cytometry. ^a^*P* \< 0.05 *vs* Ctrl, ^b^*P* \< 0.01 *vs* Ctrl, ^c^*P* \< 0.001 *vs* Ctrl, ^d^*P* \< 0.0001 *vs* Ctrl. OE: Hsa_circRNA_102610 overexpression by pLC5-ciR plasmid transfection; Ctrl: Transfection with the overexpression negative control pLC5-ciR null vector. OE + mimics: Cotransfection with the hsa_circRNA_102610 overexpression plasmid and hsa-miR-130a-3p mimics. NCM460: Normal-derived colon mucosa cell line 460; HIECs: Human intestinal epithelial cells. Bar: ×100 μm.](WJG-26-3034-g005){#F5}

Hsa_circRNA_102610 bound hsa-miR-130a-3p in NCM460 and 293T cells
-----------------------------------------------------------------

MRE analysis predicted the existence of binding sites between hsa_circRNA_102610 and hsa-miR-130a-3p. A previous study demonstrated that hsa-miR-130a-3p can reduce cell viability and suppress proliferation, invasion, and TGF-β1-induced EMT\[[@B13]\].

The above results suggest that hsa_circRNA_102610 and hsa-miR-130a-3p exhibit opposing functions. Hence, we hypothesized that hsa-circRNA_102610 might regulate cell proliferation and EMT by sponging hsa-miR-130a-3p. To verify this hypothesis, FISH and luciferase reporter assays were performed. The results (Figure [6A](#F6){ref-type="fig"}) suggested that hsa_circRNA_102610 (in green) and hsa-miR-130a-3p (in red) colocalized in both the cytoplasm and nucleus in intestinal epithelial cells. There were stronger signals near the nuclear membrane and cellular tentacles. Downregulation of hsa_circRNA_102610 attenuated these specific colocalizations in the cytoplasm (Figure [6A](#F6){ref-type="fig"}).

![Hsa_circRNA_102610 was confirmed to interact with hsa-miR-130a-3p *via* fluorescence in situ hybridization and luciferase reporter assays. A: Hsa_circRNA_102610 and hsa-miR-130a-3p were detected in normal-derived colon mucosa cell line 460 cells by fluorescence in situ hybridization using FAM- and CY3-labeled specific probes siRNA-mediated hsa_circRNA_102610 downregulation. 4', 6-diamidino-2-phenylindole was used to stain nuclei; B: Mutation site of hsa_circRNA_102610 in the miRNA response element of hsa-miR-130a-3p; C: Relative luciferase activity in normal-derived colon mucosa cell line 460 and 293T cells following transfection with psiCHECK-2 plasmids expressing the wild-type (CirWT) or mutated miRNA response element of hsa_circRNA_102610. Cells were cotransfected with hsa-miR-130a-3p mimics or negative control constructs. ^c^*P* \< 0.001 *vs* CirWT-NC, ^d^*P* \< 0.0001 *vs* CirWT-NC. Bar: ×5 μm. DAPI: 4', 6-diamidino-2-phenylindole; MRE: miRNA response element; CirWT: PsiCHECK-2 plasmids expressing the wild-type; CirMUT: PsiCHECK-2 plasmids expressing the mutated; NC: Negative control constructs; NCM460: Normal-derived colon mucosa cell line 460.](WJG-26-3034-g006){#F6}

The results of the luciferase reporter assay (Figure [6B](#F6){ref-type="fig"} and [C](#F6){ref-type="fig"}) showed that the cells cotransfected with hsa-miR-130a-3p mimics and psiCHECK-2 plasmids containing the wild-type binding sites of hsa-miR-130a-3p in hsa_circRNA_102610 exhibited lower relative luciferase activity than the cells transfected with the miR-control construct. Cells cotransfected with hsa-miR-130a-3p mimics and psiCHECK-2 containing mutated binding sites displayed no significant change in luciferase activity. These trends were consistent in 293T and NCM460 cells. These results indicate that hsa_circRNA_102610 directly binds to hsa-miR-130a-3p.

Overexpression of hsa_circRNA_102610 promoted SMAD4 and CyclinD1 protein expression
-----------------------------------------------------------------------------------

HIEC and NCM460 cell cycle progression was promoted by overexpression of hsa_circRNA_102610, and bioinformatics analysis indicated that hsa_circRNA_102610 might participate in EMT through hsa-miR-130a-3p and SMAD4 regulation. Therefore, we detected SMAD4 and CyclinD1 protein expression following hsa_circRNA_102610 upregulation or downregulation. The results in Figure [7A](#F7){ref-type="fig"} show that hsa_circRNA_102610 overexpression was accompanied by elevated expression of SMAD4 and CyclinD1. Reduced expression of SMAD4 and CyclinD1 was observed when hsa_circRNA_102610 was downregulated.

![Overexpression of hsa_circRNA_102610 promoted mothers against decapentaplegic homolog 4 and CyclinD1 protein expression, and transforming growth factor-β1-induced epithelial-mesenchymal transition in human intestinal epithelial cells and normal-derived colon mucosa cell line 460 (NCM460) cells. A: Western-blot detection of mothers against decapentaplegic homolog 4 and CyclinD1 expression following hsa_circRNA_102610 downregulation or overexpression in human intestinal epithelial and NCM460 cells. Downregulation of hsa_circRNA_102610 was conducted by siRNA (Si-1, Si-2), and a hsa-miR-130a-3p inhibitor was included to reverse the effects of the siRNAs (Si1-IN, Si2-IN). Si-NC was the negative control for siRNA interference. Hsa_circRNA_102610 was overexpressed after pLC5-ciR plasmid transfection, and hsa-miR-130a-3p mimics were included to reverse the effect of hsa_circRNA_102610 overexpression (CirOE-Mir). Cirtrl was the overexpression negative control pLC5-ciR null vector transfection; B: human intestinal epithelial cell and normal-derived colon mucosa cell line 460 (NCM460) cell morphology following transforming growth factor-β1 (TGF-β1) treatment. The cell-cell junctions were reduced in TGF-β1 treated cells, and hsa_circRNA_102610 overexpression promoted this effect. Conversely, hsa-miR-130a-3p mimics protected cells from morphological changes, and hsa_circRNA_102610 overexpression reversed this effect; C: Western blot detection of mothers against decapentaplegic homolog 4, N-Cadherin, E-Cadherin, and Vimentin in human intestinal epithelial cells and NCM460 cells following TGF-β1 treatment. CIR OE: hsa_circRNA_102610 overexpression by pLC5-ciR plasmid transfection. MIR mimic: Transfection with hsa-miR-130a-3p mimics; SMAD4: Mothers against decapentaplegic homolog 4; Cir OE: Hsa_circRNA_102610 was overexpressed after pLC5-ciR plasmid transfection; CirOE-Mir: Hsa-miR-130a-3p mimics were included to reverse the effect of hsa_circRNA_102610 overexpression; TGF-β1: Transforming growth factor-β1. Bar: × 100 μm.](WJG-26-3034-g007){#F7}

Hsa_circRNA_102610 promoted TGF-β1-induced EMT in intestinal epithelial cells by targeting hsa-miR-130a-3p
----------------------------------------------------------------------------------------------------------

Previous studies have demonstrated that hsa-miR-130a-3p could inhibit TGF-β1-induced EMT by targeting SMAD4\[[@B13],[@B20]\]. To explore whether hsa_circRNA_102610 participates in EMT regulation, cell-cell junctions were observed by phase contrast microscopy. Moreover, the expression levels of SMAD4 and EMT-related proteins (E-cadherin, N-cadherin and Vimentin) were detected by western blotting.

The results (Figure [7B](#F7){ref-type="fig"}) showed a loss of cell-cell junctions in response to TGF-β1 stimulation, while hsa-miR-130a-3p protected cells from morphological changes. Overexpression of hsa_circRNA_102610 promoted the TGF-β1-induced loss of cell-cell junctions, and hsa-miR-130a-3p mimics reversed the effects of hsa_circRNA_102610.

Regarding EMT related proteins (Figure [7C](#F7){ref-type="fig"}), TGF-β1 stimulation increased the expression of SMAD4, Vimentin and N-cadherin, but decreased the expression of E-cadherin expression. Overexpression of hsa_circRNA_102610 promoted this effect, while hsa-miR-130a-3p mimics transfection reversed it to some extent. Therefore, our studies indicate that hsa_circRNA_102610 promotes TGF-β1-induced EMT in intestinal epithelial cells by targeting hsa-miR-130a-3p.

DISCUSSION
==========

IBD is a chronic intestinal inflammatory disorder with rising incidence that includes CD and ulcerative colitis\[[@B21],[@B22]\]. Currently, the etiology of IBD is still not clear. The sensitivity and specificity of biomarkers for IBD diagnosis are limited\[[@B23],[@B24]\]. CircRNAs have recently been discovered as potential biomarkers for multiple diseases, such as colorectal cancer, hepatic carcinoma and rheumatoid arthritis\[[@B2]-[@B5]\].

Our previous studies have suggested that hsa_circRNA_102610 was valuable for the diagnosis of CD exhibiting an AUC of 0.78, a sensitivity of 60.53% and a specificity of 78.85% in ROC curve analysis\[[@B7]\]. In this study, our further analysis showed that hsa_circRNA_102610 levels were positively correlated with CALP levels. CALP is an increasingly accepted sensitive biomarker for the assessment of CD\[[@B25],[@B26]\]. Thus, although the positive correlation between hsa_circRNA_102610 and CALP in CD patients is weak (*r* = 0.359, *P* = 0.007), this finding indicates a possible role of hsa_circRNA_102610 in CD. However, the exact mechanism of hsa_circRNA_102610 in the development of CD is still unclear.

Given this result, we next overexpressed or knocked down hsa_circRNA_102610 in intestinal epithelial cells. The CCK8 and EdU staining results demonstrated that cell growth was promoted by hsa_circRNA_102610 overexpression. Cell cycle progression was promoted by hsa_circRNA_102610, as indicated by increased proportions of S and G2 phase cells, while knockdown of hsa_circRNA_102610 had the opposite effect. Excessive cell growth is strongly associated with inflammation\[[@B27]\]. We infer that cell growth is probably induced by overexpression of hsa_circRNA_102610 in CD patients and we hypothesize that chronic intestinal inflammation may be related to upregulation of hsa_circRNA_102610. However, the above hypothesis should be confirmed *in vivo* in animal models. This will be the focus of our future studies.

It has been widely reported that circRNAs act as sponges of miRNAs\[[@B4]\]. The MRE analysis in this study suggested that interactions occur between hsa_circRNA_102610 and 5 miRNAs (Figure [3C](#F3){ref-type="fig"}). Among them, an interaction with hsa-miR-130a-3p was predicted to be the most likely one. It has been reported that hsa-miR-130a-3p participates in EMT inhibition and cell proliferation in various cell types in a SMAD4-dependent manner\[[@B12]-[@B14]\]. Thus, hsa_circRNA_102610 is likely involved in regulating the downstream pathways of hsa-miR-130a-3p. The RT-qPCR analysis results obtained with clinical samples showed that downregulation of hsa-miR-130a-3p was inversely correlated with upregulation of hsa_circRNA_102610 in CD. *In vitro* studies demonstrated that hsa-miR-130a-3p mimics could reverse the growth promoting effect of hsa_circRNA_102610 overexpression on intestinal epithelial cells. Conversely, knockdown of hsa_circRNA_102610 blocked cell growth, and a hsa-miR-130a-3p inhibitor reversed these effects. In addition, FISH and luciferase reporter assays indicated a direct interaction of hsa_circRNA_102610 with hsa-miR-130a-3p. Thus, the research results in this study suggest that hsa_circRNA_102610 play roles in the regulation of intestinal epithelial cell proliferation by sponging hsa-miR-130a-3p.

Intestinal strictures and fistulas are common in CD. The mechanism of intestinal fibrosis is complex, and includes epigenetic and genetic modulations, microbiotic regulation, and extracellular matrix-related processes, among other factors\[[@B28]\]. Among these factors, EMT is an important contributor to the production of new mesenchymal cells from epithelial tissue\[[@B17],[@B29]\]. Research by Shameer and colleagues demonstrated that epithelial expression of the EMT marker Vimentin was significantly elevated in a strictured CD group\[[@B19]\]. It is becoming apparent that EMT participates in CD-associated intestinal fibrosis and fistulas\[[@B17],[@B30]\]. In addition, it is universally accepted that inflammation can induce cell proliferation\[[@B31]\]. In our study, the results of CCK-8 assays, EdU staining, and cell cycle detection by flow cytometry suggested that hsa_circRNA_102610 overexpression could promote HIEC and NCM460 proliferation and upregulate cyclinD1 expression, as verified by western blotting. The expression of the EMT related protein E-cadherin was reduced in response to hsa_circRNA_102610 overexpression, while the expression of SMAD4, Vimentin, N-cadherin and the cell cycle related protein CyclinD1 was upregulated. These results further suggested that hsa_circRNA_102610 regulates specific signaling pathways downstream of hsa-miR-130a-3p in a SMAD4-dependent manner.

In conclusion, we studied, for the first time, the mechanism by which hsa_circRNA_102610 participates in the regulation of intestinal epithelial cell EMT and proliferation, based on our previous discovery that hsa_circRNA_102610 is upregulated in CD patients\[[@B7]\]. The results of this study imply that hsa\_ circRNA_102610 can promote the growth and TGF-β1-induced EMT of intestinal epithelial cells by sponging hsa-miR-130a-3p (Figure [8](#F8){ref-type="fig"})\[[@B32],[@B33]\]. It has been reported that synthetic circRNAs can act as sponges to competitively inhibit miRNAs of interest. Accordingly, hsa_circRNA_102610 may serve as a potential target for CD therapy and novel drug research. Externally delivered hsa-miR-130a-3p could possibly act as a sponge of hsa_circRNA_102610.

![Proposed model by which hsa_circRNA_102610 promotes growth and transforming growth factor-β1-induced epithelial-mesenchymal transition of intestinal epithelial cells by sponging hsa-miR-130a-3p. This schematic was generated by Pathway Builder Tool 2.0. Hsa_circRNA_102610 promotes TGFβ1-induced epithelial-mesenchymal transition by sponging hsa-miR-130a-3p and blocking the inhibitory effect of hsa-miR-130a-3p on Mothers against decapentaplegic homolog 4. The expression of CyclinD1, Vimentin and N-Cadherin is promoted, while the expression of E-Cadherin is inhibited. SMAD4: Mothers against decapentaplegic homolog 4; TGF-β1: Transforming growth factor-β1.](WJG-26-3034-g008){#F8}

However, there were limitations in our study. First, this research was conducted only on CD patients and intestinal epithelial cells. *In vivo* mechanistic studies should be carried out on animal models to further confirm the role of hsa_circRNA_102610 in CD development. Second, how hsa_circRNA_102610-mediated regulation of intestinal epithelial cell EMT and proliferation plays a role in CD pathological processes, such as the formation of intestinal strictures, requires extensive investigation.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

CircRNAs are considered valuable diagnostic biomarkers for Crohn\'s disease (CD). Our previous study demonstrated that hsa_circRNA_102610 was upregulated in CD patients. Furthermore, miRNA response element (MRE) analysis suggested the existence of a potential interaction between hsa_circRNA_102610 and hsa-miR-130a-3p. Current evidence supports the views that epithelial-mesenchymal transition (EMT) plays an important role in CD pathogenesis, and that hsa-miR-130a-3p can inhibit transforming growth factor-β1 (TGF-β1)-induced EMT.

Research motivation
-------------------

Further investigation is required to explore the mechanism of hsa_circRNA_102610 in the pathogenesis of CD.

Research objectives
-------------------

This study was designed to investigate whether the upregulation of hsa_circRNA_102610 correlates with the degree of inflammation in Crohn\'s disease. The CALP level, C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) were included in the correlation analysis. Furthermore, the roles that hsa_circRNA_102610 may play in the proliferation and EMT of intestinal epithelial cells were studied in normal-derived colon mucosa cell line 460 (NCM460) and human intestinal epithelial cells (HIECs).

Research methods
----------------

The relative expression levels of hsa_circRNA_102610 and hsa-miR-130a-3p in CD patients were detected by quantitative reverse transcription-polymerase chain reaction. The proliferation of HIECs and NCM460 cells was detected by cell counting kit-8, EdU staining and cell cycle assays following overexpression or downregulation of hsa_circRNA_102610. Cell proliferation assays were performed as described above in a rescue experiment with hsa-miR-130a-3p mimics. The interaction of hsa_circRNA_102610 and hsa-miR-130a-3p was verified by fluorescence in situ hybridization and dual luciferase reporter assays. The relative expression levels of CyclinD1, SMAD4, E-cadherin, N-cadherin and Vimentin were detected by western blotting following hsa_circRNA_102610 overexpression, TGF-β1-induced EMT or hsa-miR-130a-3p mimic transfection (in rescue experiments).

Research results
----------------

Upregulation of hsa_circRNA_102610 was determined to be positively correlated with elevated fecal calprotectin levels in CD (*r* = 0.359, *P* = 0.007) by Pearson correlation analysis. Hsa_circRNA_102610 promoted the proliferation of HIECs and NCM460 cells, while hsa-miR-130a-3p reversed the cell proliferation-promoting effects of hsa-circRNA_102610. Fluorescence in situ hybridization and dual luciferase reporter assays showed that hsa_circRNA_102610 directly bound hsa-miR-130a-3p in NCM460 and 293T cells. An inverse correlation between downregulation of hsa-miR-130a-3p and upregulation of hsa_circRNA_102610 in CD patients was observed (*r* = -0.290, *P* = 0.024) by Pearson correlation analysis. Moreover, overexpression of hsa_circRNA_102610 promoted SMAD4 and CyclinD1 protein expression, as validated by western blotting. Furthermore, overexpression of hsa_circRNA_102610 promoted TGF-β1-induced EMT in HIECs and NCM460 cells *via* targeting of hsa-miR-130a-3p, with increased expression of Vimentin and N-cadherin and decreased expression of E-cadherin.

Research conclusions
--------------------

Hsa_circRNA_102610 upregulation in CD patients could promote the proliferation and EMT of intestinal epithelial cells *via* sponging of hsa-miR-130a-3p.

Research perspectives
---------------------

Hsa_circRNA_102610 may serve as a potential target for CD therapy and novel drug research. Externally delivered hsa-miR-130a-3p could possibly act as a sponge of hsa_circRNA_102610.
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